statistiche ricercatore

Continente	#
NA - Nord America	798
AS - Asia	797
EU - Europa	298
SA - Sud America	144
AF - Africa	31
Continente sconosciuto - Info sul continente non disponibili	24
OC - Oceania	1
Totale	2.093

Nazione	#
US - Stati Uniti d'America	734
CN - Cina	267
SG - Singapore	224
IT - Italia	129
VN - Vietnam	121
BR - Brasile	105
HK - Hong Kong	43
KR - Corea	40
GB - Regno Unito	33
RU - Federazione Russa	24
FR - Francia	22
CA - Canada	21
SE - Svezia	21
AR - Argentina	20
IN - India	20
MX - Messico	19
NL - Olanda	18
BD - Bangladesh	14
DE - Germania	13
ZA - Sudafrica	13
PL - Polonia	12
TR - Turchia	12
ID - Indonesia	10
JP - Giappone	9
EC - Ecuador	8
IQ - Iraq	8
CO - Colombia	6
FI - Finlandia	6
UA - Ucraina	6
SV - El Salvador	5
IL - Israele	4
SA - Arabia Saudita	4
TT - Trinidad e Tobago	4
UZ - Uzbekistan	4
AE - Emirati Arabi Uniti	3
DZ - Algeria	3
EG - Egitto	3
HN - Honduras	3
HR - Croazia	3
MA - Marocco	3
NI - Nicaragua	3
PK - Pakistan	3
TN - Tunisia	3
AT - Austria	2
AZ - Azerbaigian	2
CH - Svizzera	2
CL - Cile	2
CR - Costa Rica	2
GP - Guadalupe	2
GR - Grecia	2
MY - Malesia	2
PA - Panama	2
PE - Perù	2
RO - Romania	2
SC - Seychelles	2
AU - Australia	1
BZ - Belize	1
CI - Costa d'Avorio	1
CW - ???statistics.table.value.countryCode.CW???	1
ES - Italia	1
ET - Etiopia	1
GT - Guatemala	1
JO - Giordania	1
KE - Kenya	1
KG - Kirghizistan	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LT - Lituania	1
PH - Filippine	1
PR - Porto Rico	1
PT - Portogallo	1
SN - Senegal	1
SR - Suriname	1
SY - Repubblica araba siriana	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	2.071

Nome	#
Patient derived organoids are an useful tool to investigate Hippo pathway involvement in lung cancer	183
The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling	173
Harnessing NK Cell Potential Against NSCLC	162
Implementing an organoid platform to assess efficacy of PHD inhibitors as anti-cancer agents	161
Dissecting the role of lncRNAs in promoting Natural Killer cytotoxicity in Non-Small Cell Lung Cancer models	155
PHD2 (EGLN1) is a novel therapeutic target in KRAS-mutated lung carcinoma	155
LncRNA TAZ-AS202 promotes lung cancer progression through the regulation of the E2F1 transcription factor	142
Exploring EGLN1/PHD2 role in KRAS mutated lung cancer: insights into mitochondrial modulation and therapeutic opportunities	125
A Two-Step Protocol for Isolation and Maintenance of Lung Cancer Primary 3D Cultures	124
Harnessing the hypoxia pathway to set a new therapeutic strategy for KRAS-mutated lung adenocarcinoma	118
Unraveling NK Cell-Mediated Cytotoxicity in NSCLC	113
Leveraging NK Cell Potential Against NSCLC: insights from long-non coding RNAs	111
Targeting EGLN1 to Overcome Drug Resistance in KRAS-Mutant Lung Adenocarcinoma: A Patient-Derived Organoid Study	107
Characterization of EGLN1 as a pro-oncogenic factor and pharmacological target in lung cancer	104
null	83
Exploring EGLN1 as a therapeutic target for KRAS mutated lung cancer	77
Totale	2.093

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2024/2025	365	0	19	17	24	62	46	44	22	43	15	39	34
2025/2026	1.418	74	92	196	245	215	70	181	62	141	74	50	18
2026/2027	310	58	43	87	107	15	0	0	0	0	0	0	0
Totale													2.093